ED Tracking Sheet Implementation
NCT05213923
Infections, Inflammation
Lebanon, New Hampshire, United States
View Trial DetailsNCT Number: NCT00448968
The purpose of this study is to determine if levels of ischemia modified albumin (IMA) in blood are elevated in patients with suspected infection and are predictive of severity of illness in patients with sepsis.
In order to compare subjects with infection to those without infection who are representative of the ED population at each site, a group of non-infected control patients will be enrolled. Each hospital will enroll subjects with age (by decade) and sex matched controls to reflect the population of subjects suspected of infection.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Sepsis is an unconquered challenge in medicine, affecting people of all ages and demographics. Severe sepsis affects approximately 751,000 patients in the United States per annum, with healthcare costs approaching $16.7 billion dollars a year. Mortality from severe sepsis and septic shock approaches 30 - 70 % with 215,000 deaths annually. Thus, sepsis is a disease with healthcare dollars and mortality rates approaching those of heart disease and cancer.
Identifying patients with sepsis, and in particular hypoperfusion, is a challenge to the clinician. A variety of clinical and laboratory findings are helpful, but there is no single test to identify sepsis or assess its severity.
Ischemia and reactive oxygen species play a significant role in the pathogenesis of sepsis. Moreover, there is evidence to suggest that septic shock results in dysfunction of autoregulatory mechanisms and misdistribution of blood flow, precipitating both regional and global ischemia. A method that can help rapidly assess hypoperfusion would be clinically useful. Ischemia modified albumin (IMA) is a potential marker for ischemia in acute coronary syndrome patients; thus, it is hypothesized that IMA may be also useful as a prognostic biomarker for clinical identification of infection and the severity of illness in patients with sepsis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Sepsis Subjects:
Exclusion criteria
for Sepsis Subjects:
Inclusion criteria
for Control Subjects:
Exclusion criteria
for Control Subjects:
Inverness Medical Innovations
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05213923
Infections, Inflammation
Lebanon, New Hampshire, United States
View Trial DetailsNCT03077672
Disease Attributes, Emergencies
Brooklyn, New York, United States
View Trial DetailsNCT03037281
Infections, Inflammation
Leicester, Leicestershire, United Kingdom
View Trial DetailsNCT05469048
Infections, Inflammation
Los Angeles, California, United States
View Trial Details